Head to Head Analysis: Aevi Genomic Medicine (GNMX) versus SIGA Technologies (SIGA)

Aevi Genomic Medicine (NASDAQ: GNMX) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

16.8% of Aevi Genomic Medicine shares are held by institutional investors. Comparatively, 6.7% of SIGA Technologies shares are held by institutional investors. 15.2% of Aevi Genomic Medicine shares are held by insiders. Comparatively, 4.7% of SIGA Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Aevi Genomic Medicine and SIGA Technologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aevi Genomic Medicine N/A N/A -$41.90 million ($1.13) -1.19
SIGA Technologies $14.99 million 26.06 -$39.69 million ($0.49) -10.10

SIGA Technologies has higher revenue and earnings than Aevi Genomic Medicine. SIGA Technologies is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aevi Genomic Medicine has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aevi Genomic Medicine and SIGA Technologies, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aevi Genomic Medicine 0 1 1 0 2.50
SIGA Technologies 0 0 0 0 N/A

Aevi Genomic Medicine presently has a consensus target price of $4.25, indicating a potential upside of 217.16%. Given Aevi Genomic Medicine’s higher possible upside, analysts plainly believe Aevi Genomic Medicine is more favorable than SIGA Technologies.

Profitability

This table compares Aevi Genomic Medicine and SIGA Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aevi Genomic Medicine N/A -163.88% -130.14%
SIGA Technologies -201.85% N/A -23.22%

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

SIGA Technologies Company Profile

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply